Literature DB >> 12967527

Catastrophic antiphospholipid syndrome.

Ronald A Asherson1, Ricard Cervera.   

Abstract

Catastrophic antiphospholipid syndrome, defined and documented in 1992, is a potentially fatal complication seen in patients with antiphospholipid antibody. It may arise de novo in patients not previously suspected as having an antiphospholipid syndrome, or it may complicate the course of patients currently treated for this syndrome. Precipitating or "trigger" factors have been identified in 55% of patients; the most common of these factors is infection. The precipitating factors should be avoided or energetically treated in patients with the antiphospholipid syndrome in order to prevent this "catastrophic" course. The clinical manifestations are those of multiorgan failure, and unusual vessels or organs can be involved. Treatment of the condition, with emphasis on effective anticoagulation, intravenous steroids, intravenous immunoglobulin, or plasma exchange, should be aggressive to achieve a satisfactory outcome. Regrettably, despite all available therapeutic options at this time, the mortality is still high (greater than 50%).

Entities:  

Mesh:

Year:  2003        PMID: 12967527     DOI: 10.1007/s11926-003-0031-7

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  15 in total

1.  The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome--molecular mimicry?

Authors:  R A Asherson; Y Shoenfeld
Journal:  J Rheumatol       Date:  2000-01       Impact factor: 4.666

Review 2.  Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients.

Authors:  R A Asherson; R Cervera; J C Piette; Y Shoenfeld; G Espinosa; M A Petri; E Lim; T C Lau; A Gurjal; A Jedryka-Góral; H Chwalinska-Sadowska; R J Dibner; J Rojas-Rodríguez; M García-Carrasco; J T Grandone; A L Parke; P Barbosa; C Vasconcelos; M Ramos-Casals; J Font; M Ingelmo
Journal:  Medicine (Baltimore)       Date:  2001-11       Impact factor: 1.889

3.  Catastrophic antiphospholipid syndrome: remission following leg amputation in 2 cases.

Authors:  H Amital; Y Levy; C Davidson; I Lundberg; A Harju; Y Kosach; R A Asherson; Y Shoenfeld
Journal:  Semin Arthritis Rheum       Date:  2001-10       Impact factor: 5.532

Review 4.  The catastrophic antiphospholipid syndrome.

Authors:  R A Asherson
Journal:  J Rheumatol       Date:  1992-04       Impact factor: 4.666

5.  Catastrophic antiphospholipid antibody syndrome in primary systemic sclerosis.

Authors:  D Kane; F McSweeney; N Swan; B Bresnihan
Journal:  J Rheumatol       Date:  1998-04       Impact factor: 4.666

6.  Tests for heparin-induced thrombocytopenia in primary antiphospholipid syndrome.

Authors:  D Lasne; R Saffroy; C Bachelot; A Vincenot; F Rendu; T Papo; M Aiach; J C Piette
Journal:  Br J Haematol       Date:  1997-06       Impact factor: 6.998

7.  Catastrophic antiphospholipid syndrome: proposed guidelines for diagnosis and treatment.

Authors:  Ronald A Asherson; Gerard Espinosa; Ricard Cervera; Josep Font; Joan Carles Reverter
Journal:  J Clin Rheumatol       Date:  2002-06       Impact factor: 3.517

Review 8.  Thrombotic storm: when thrombosis begets thrombosis.

Authors:  C S Kitchens
Journal:  Am J Med       Date:  1998-04       Impact factor: 4.965

9.  Diagnosis of heparin-induced thrombocytopenia. Still a journey, not yet a destination.

Authors:  J G Kelton; T E Warkentin
Journal:  Am J Clin Pathol       Date:  1995-12       Impact factor: 2.493

10.  Long term outcome of catastrophic antiphospholipid syndrome survivors.

Authors:  D Erkan; R A Asherson; G Espinosa; R Cervera; J Font; J-C Piette; M D Lockshin
Journal:  Ann Rheum Dis       Date:  2003-06       Impact factor: 19.103

View more
  5 in total

1.  Delayed catastrophic antiphospholipid syndrome after massive cerebral infarction.

Authors:  Wei Hsi Chen; Hung Sheng Lin; Yi Fen Kao; Jia Shou Liu
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

Review 2.  Neurologic Manifestations of Catastrophic Antiphospholipid Syndrome.

Authors:  Rafid Mustafa
Journal:  Curr Neurol Neurosci Rep       Date:  2022-08-30       Impact factor: 6.030

3.  Relationship and significance between anti-beta2-glycoprotein I antibodies and platelet activation state in patients with ulcerative colitis.

Authors:  Yan-Hang Gao; Pu-Jun Gao; Chun-Guang Wang; Xiao-Cong Wang; Yun-Feng Piao
Journal:  World J Gastroenterol       Date:  2008-02-07       Impact factor: 5.742

Review 4.  Organ Damage and Quality of Life in Antiphospholipid Syndrome.

Authors:  P Alba; J A Gómez-Puerta; M V Goycochea-Robles; M C Amigo
Journal:  Curr Rheumatol Rep       Date:  2016-02       Impact factor: 4.592

5.  Extensive vascular occlusions as initial presentations of systemic lupus erythematosis. A case report and review of literature.

Authors:  Mohamed Elsharawy; Manal Hasan; Ibrahiem Saeed Abdul-Rahman; Bandar Al-Dhofairy; Ayman Elsaid
Journal:  Avicenna J Med       Date:  2015 Apr-Jun
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.